Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06500819 · ClinicalTrials.gov registry record · Phase 1
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
A Phase 1 study of Sarcoma and Neuroblastoma, sponsored by Crystal Mackall, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06500819: Recruiting Phase 1 study of Sarcoma and Neuroblastoma, sponsored by Crystal Mackall, MD.
NCT06500819 is a Phase 1 study of Sarcoma and Neuroblastoma that is actively recruiting participants, run by Crystal Mackall, MD. The registered enrollment target is 41 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06500819, a Phase 1 study of Sarcoma and Neuroblastoma, is actively recruiting participants, sponsored by Crystal Mackall, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.
Primary Outcome
Feasibility of manufacturing autologous T cells transduced with Ef1a-CAR276 lentiviral vector expressing B7-H3 Chimeric Antigen Receptor (B7-H3-CART), using the Miltenyi CliniMACS Prodigy® system with dasatinib and protamine sulfate.
Conditions Studied
Interventions
- DRUG B7-H3CART Dose (Intravenous)
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
What NCT06500819 shows while recruiting
NCT06500819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which B7-H3CART Dose (Intravenous) is the first listed.
NCT06500819 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06500819 about?
NCT06500819 is a clinical study titled "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors". The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.
What is the current status of trial NCT06500819?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-07-11. Estimated completion is 2029-07.
What conditions does trial NCT06500819 study?
This clinical trial studies the following conditions: Sarcoma, Neuroblastoma, Osteosarcoma.
What interventions are being tested in trial NCT06500819?
The interventions under investigation include: B7-H3CART Dose (Intravenous) (DRUG).
Who is sponsoring clinical trial NCT06500819?
This trial is sponsored by Crystal Mackall, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06500819 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06500819's enrollment target sits among peer trials
41 73rd of 122 higher than 49 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A Study of CRD3874-SI in People With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy